These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 37679770)
1. CUDC-907, a dual PI3K/histone deacetylase inhibitor, increases meta-iodobenzylguanidine uptake ( Grand-Guillaume J; Mansi R; Gaonkar RH; Zanger S; Fani M; Eugster PJ; Beck Popovic M; Grouzmann E; Abid K J Transl Med; 2023 Sep; 21(1):604. PubMed ID: 37679770 [TBL] [Abstract][Full Text] [Related]
2. Increased uptake of [¹²³I]meta-iodobenzylguanidine, [¹⁸F]fluorodopamine, and [³H]norepinephrine in mouse pheochromocytoma cells and tumors after treatment with the histone deacetylase inhibitors. Martiniova L; Perera SM; Brouwers FM; Alesci S; Abu-Asab M; Marvelle AF; Kiesewetter DO; Thomasson D; Morris JC; Kvetnansky R; Tischler AS; Reynolds JC; Fojo AT; Pacak K Endocr Relat Cancer; 2011 Feb; 18(1):143-57. PubMed ID: 21098082 [TBL] [Abstract][Full Text] [Related]
3. Vorinostat increases expression of functional norepinephrine transporter in neuroblastoma in vitro and in vivo model systems. More SS; Itsara M; Yang X; Geier EG; Tadano MK; Seo Y; Vanbrocklin HF; Weiss WA; Mueller S; Haas-Kogan DA; Dubois SG; Matthay KK; Giacomini KM Clin Cancer Res; 2011 Apr; 17(8):2339-49. PubMed ID: 21421857 [TBL] [Abstract][Full Text] [Related]
4. Potential for Increasing Uptake of Radiolabeled Pollard JH; Menda Y; Zamba KD; Madsen M; O'Dorisio MS; O'Dorisio T; Bushnell D Cancer Biother Radiopharm; 2021 Oct; 36(8):632-641. PubMed ID: 34252288 [No Abstract] [Full Text] [Related]
5. Imaging the norepinephrine transporter in neuroblastoma: a comparison of [18F]-MFBG and 123I-MIBG. Zhang H; Huang R; Cheung NK; Guo H; Zanzonico PB; Thaler HT; Lewis JS; Blasberg RG Clin Cancer Res; 2014 Apr; 20(8):2182-91. PubMed ID: 24573553 [TBL] [Abstract][Full Text] [Related]
6. Tumor dosimetry using [124I]m-iodobenzylguanidine microPET/CT for [131I]m-iodobenzylguanidine treatment of neuroblastoma in a murine xenograft model. Seo Y; Gustafson WC; Dannoon SF; Nekritz EA; Lee CL; Murphy ST; VanBrocklin HF; Hernandez-Pampaloni M; Haas-Kogan DA; Weiss WA; Matthay KK Mol Imaging Biol; 2012 Dec; 14(6):735-42. PubMed ID: 22382618 [TBL] [Abstract][Full Text] [Related]
7. Improved selectivity of mIBG uptake into neuroblastoma cells in vitro and in vivo by inhibition of organic cation transporter 3 uptake using clinically approved corticosteroids. Bayer M; Schmitt J; Dittmann H; Handgretinger R; Bruchelt G; Sauter AW Nucl Med Biol; 2016 Sep; 43(9):543-551. PubMed ID: 27376201 [TBL] [Abstract][Full Text] [Related]
8. Specific binding and uptake of 131I-MIBG and 111In-octreotide in metastatic paraganglioma--tools for choice of radionuclide therapy. Spetz J; Dalmo J; Nilsson O; Wängberg B; Ahlman H; Forssell-Aronsson E Horm Metab Res; 2012 May; 44(5):400-4. PubMed ID: 22566195 [TBL] [Abstract][Full Text] [Related]
9. The Plasma Membrane Monoamine Transporter is Highly Expressed in Neuroblastoma and Functions as an mIBG Transporter. Vieira LS; Zhang Y; López Quiñones AJ; Hu T; Singh DK; Stevens J; Prasad B; Park JR; Wang J J Pharmacol Exp Ther; 2023 Dec; 387(3):239-248. PubMed ID: 37541765 [TBL] [Abstract][Full Text] [Related]
10. Uptake of mIBG and catecholamines in noradrenaline- and organic cation transporter-expressing cells: potential use of corticosterone for a preferred uptake in neuroblastoma- and pheochromocytoma cells. Bayer M; Kuçi Z; Schömig E; Gründemann D; Dittmann H; Handgretinger R; Bruchelt G Nucl Med Biol; 2009 Apr; 36(3):287-94. PubMed ID: 19324274 [TBL] [Abstract][Full Text] [Related]
11. A 4-methyl-substituted meta-iodobenzylguanidine analogue with prolonged retention in human neuroblastoma cells. Vaidyanathan G; Welsh PC; Vitorello KC; Snyder S; Friedman HS; Zalutsky MR Eur J Nucl Med Mol Imaging; 2004 Oct; 31(10):1362-70. PubMed ID: 15205923 [TBL] [Abstract][Full Text] [Related]
12. Meta-iodobenzylguanidine induces growth inhibition and apoptosis of neuroendocrine gastrointestinal tumor cells. Höpfner M; Sutter AP; Beck NI; Barthel B; Maaser K; Jockers-Scherübl MC; Zeitz M; Scherübl H Int J Cancer; 2002 Sep; 101(3):210-6. PubMed ID: 12209970 [TBL] [Abstract][Full Text] [Related]
13. Antitumor activity and mechanism of resistance of the novel HDAC and PI3K dual inhibitor CUDC-907 in pancreatic cancer. Liu S; Zhao S; Dong Y; Wang T; Niu X; Zhao L; Wang G Cancer Chemother Pharmacol; 2021 Mar; 87(3):415-423. PubMed ID: 33392641 [TBL] [Abstract][Full Text] [Related]
14. Uptake of meta-iodobenzylguanidine in neuroendocrine tumours is mediated by vesicular monoamine transporters. Kölby L; Bernhardt P; Levin-Jakobsen AM; Johanson V; Wängberg B; Ahlman H; Forssell-Aronsson E; Nilsson O Br J Cancer; 2003 Oct; 89(7):1383-8. PubMed ID: 14520475 [TBL] [Abstract][Full Text] [Related]
15. Selective serotonin reuptake inhibitors (SSRIs) prevent meta-iodobenzylguanidine (MIBG) uptake in platelets without affecting neuroblastoma tumor uptake. Blom T; Meinsma R; Rutgers M; Buitenhuis C; Dekken-Van den Burg M; van Kuilenburg ABP; Tytgat GAM EJNMMI Res; 2020 Jul; 10(1):78. PubMed ID: 32642907 [TBL] [Abstract][Full Text] [Related]
16. A novel approach in the treatment of neuroendocrine gastrointestinal tumors: additive antiproliferative effects of interferon-gamma and meta-iodobenzylguanidine. Höpfner M; Sutter AP; Huether A; Ahnert-Hilger G; Scherübl H BMC Cancer; 2004 May; 4():23. PubMed ID: 15154969 [TBL] [Abstract][Full Text] [Related]
17. Antileukemic activity and mechanism of action of the novel PI3K and histone deacetylase dual inhibitor CUDC-907 in acute myeloid leukemia. Li X; Su Y; Madlambayan G; Edwards H; Polin L; Kushner J; Dzinic SH; White K; Ma J; Knight T; Wang G; Wang Y; Yang J; Taub JW; Lin H; Ge Y Haematologica; 2019 Nov; 104(11):2225-2240. PubMed ID: 30819918 [TBL] [Abstract][Full Text] [Related]
18. Dexmedetomidine does not interfere with meta-iodobenzylguanidine (MIBG) uptake at clinically relevant concentrations. Batra V; Makvandi M; Zuppa AF; Patel N; Elias J; Pryma DA; Maris JM Pediatr Blood Cancer; 2017 Apr; 64(4):. PubMed ID: 27654664 [TBL] [Abstract][Full Text] [Related]
19. The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer. Ma L; Bian X; Lin W J Exp Clin Cancer Res; 2020 Oct; 39(1):219. PubMed ID: 33069237 [TBL] [Abstract][Full Text] [Related]
20. Semiquantitative 123I-Metaiodobenzylguanidine Scintigraphy to Distinguish Pheochromocytoma and Paraganglioma from Physiologic Adrenal Uptake and Its Correlation with Genotype-Dependent Expression of Catecholamine Transporters. van Berkel A; Rao JU; Lenders JW; Pellegata NS; Kusters B; Piscaer I; Hermus AR; Plantinga TS; Langenhuijsen JF; Vriens D; Janssen MJ; Gotthardt M; Timmers HJ J Nucl Med; 2015 Jun; 56(6):839-46. PubMed ID: 25883126 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]